1. Home
  2. CFFN vs NTLA Comparison

CFFN vs NTLA Comparison

Compare CFFN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

HOLD

Current Price

$6.75

Market Cap

905.3M

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$14.67

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFFN
NTLA
Founded
1893
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
905.3M
986.9M
IPO Year
1999
2016

Fundamental Metrics

Financial Performance
Metric
CFFN
NTLA
Price
$6.75
$14.67
Analyst Decision
Hold
Buy
Analyst Count
2
19
Target Price
$6.75
$17.32
AVG Volume (30 Days)
885.5K
5.4M
Earning Date
01-28-2026
02-26-2026
Dividend Yield
4.88%
N/A
EPS Growth
79.31
N/A
EPS
0.52
N/A
Revenue
$200,291,000.00
$57,528,000.00
Revenue This Year
$16.44
$1.96
Revenue Next Year
$3.40
N/A
P/E Ratio
$13.40
N/A
Revenue Growth
20.62
33.52
52 Week Low
$4.90
$5.90
52 Week High
$7.31
$28.25

Technical Indicators

Market Signals
Indicator
CFFN
NTLA
Relative Strength Index (RSI) 48.43 72.71
Support Level $6.61 $11.34
Resistance Level $7.13 $9.62
Average True Range (ATR) 0.17 1.08
MACD 0.00 0.53
Stochastic Oscillator 36.36 81.16

Price Performance

Historical Comparison
CFFN
NTLA

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: